New England Journal of Medicine November 19, 2026

Assessing Multiple Treatment Regimens for Tuberculosis

Hanif Esmail, Nicholas I. Paton, Jodie A. Schildkraut, Ilaria Motta, et al.

Bottom Line

In a phase 2 platform trial, two novel four-drug regimens containing either ganfeborole or BTZ-043 demonstrated promising early bactericidal activity and acceptable safety profiles, supporting their progression to further evaluation for shortening tuberculosis treatment.

Key Findings

1. Two novel regimens, ganfeborole-bedaquiline-pretomanid-moxifloxacin (BPMG) and BTZ-043-bedaquiline-delamanid-moxifloxacin (BDMT), were identified as promising for further clinical evaluation.
2. The primary endpoint, log 10 (time to positivity) slope, was 0.129 log 10 (days) per week (95% CrI, 0.112 to 0.146) with BPMG and 0.142 log 10 (days) per week (95% CrI, 0.126 to 0.160) with BDMT.
3. In comparison, the standard HRZE regimen achieved a slope of 0.118 log 10 (days) per week (95% CrI, 0.105 to 0.131).
4. The relative difference compared to HRZE was 9.1% (95% CrI, -8.6 to 29.0) for BPMG and 20.5% (95% CrI, 2.7 to 41.1) for BDMT, yielding posterior probabilities of superiority of 0.83 and 0.99, respectively.
5. Grade 3 or higher adverse events occurred in 38% of the BPMG group (none discontinued), 28% of the BDMT group (one discontinued due to a drug reaction with eosinophilia and systemic symptoms), and 24% of the HRZE group (none discontinued).
6. A regimen containing bedaquiline, moxifloxacin, pyrazinamide, and BTZ-043 was prematurely discontinued due to hepatotoxic effects.

Study Design

Design
Phase 2 RCT
Open-Label
Sample
401
Patients
Duration
12 wk
Median
Setting
Multicenter, 5 countries
Population Participants with rifampin-susceptible pulmonary tuberculosis
Intervention Ten novel four-drug combinations for 16 weeks containing ganfeborole, BTZ-043, or both (along with bedaquiline, delamanid, moxifloxacin, pyrazinamide, pretomanid, and linezolid)
Comparator Standard four-drug combination (isoniazid-rifampin-pyrazinamide-ethambutol; HRZE) for 24 weeks
Outcome Log 10 (time to positivity) slope (rate of change from baseline to week 12 in the time to Mycobacterium tuberculosis growth in a positive sputum culture)

Study Limitations

• The study evaluated an early surrogate marker of efficacy (bactericidal activity up to week 12) rather than definitive long-term clinical outcomes such as relapse rates.
• The trial was designed to select promising regimens for further study rather than to provide definitively powered characterizations of clinical efficacy.
• The platform design resulted in relatively small sample sizes per treatment arm, limiting the ability to detect rare adverse events or precisely estimate subtle safety differences.
• The discontinuation of one BTZ-043-containing arm highlights the unpredictable nature of compounded toxicities when testing multiple novel combinations.

Clinical Significance

This landmark platform trial validates the use of an innovative Bayesian adaptive design to efficiently evaluate multiple multi-drug combinations in parallel. By identifying two novel 16-week regimens featuring new drug classes (ganfeborole and BTZ-043) with high bactericidal activity and acceptable safety profiles, it represents a crucial step toward developing shorter, highly active, and safer tuberculosis treatments that can circumvent existing resistance mechanisms.

Historical Context

Standard therapy for drug-susceptible tuberculosis has traditionally relied on a 6-month regimen of HRZE, which can be burdensome and prone to adherence challenges. Although recent advances have introduced 4-month regimens containing rifapentine and moxifloxacin, there is a pressing global need for even shorter, better-tolerated therapies that feature novel mechanisms of action to counter rising antimicrobial resistance. The PARADIGM4TB trial reflects a paradigm shift in TB drug development by employing a platform trial design to screen entirely novel multi-drug regimens concurrently.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What are the mechanisms of action for the novel anti-tubercular agents ganfeborole and BTZ-043, and why is targeting multiple distinct metabolic pathways simultaneously critical in the treatment of Mycobacterium tuberculosis?

Key Response

Ganfeborole inhibits leucyl-tRNA synthetase, halting protein synthesis, while BTZ-043 targets DprE1, an enzyme essential for cell wall arabinogalactan synthesis. Combining agents with distinct mechanisms (e.g., protein synthesis vs. cell wall integrity) is crucial to prevent the rapid emergence of resistance and to effectively target both actively dividing and persistent mycobacterial subpopulations.

Resident
Resident

How does early bactericidal activity (EBA) measured in a Phase 2 trial translate to clinical outcomes, and what specific safety parameters must be monitored when introducing these novel four-drug regimens for drug-susceptible TB?

Key Response

EBA measures the daily fall in sputum colony-forming units during the first 14 days, reflecting a drug's ability to rapidly kill dividing bacilli and reduce infectiousness. However, EBA does not perfectly predict sterilizing activity (the ability to prevent relapse). Residents must recognize that while high EBA is promising, intensive monitoring for overlapping toxicities like hepatotoxicity, QTc prolongation, and cytopenias remains essential before widespread clinical adoption.

Fellow
Fellow

In the context of the evolving TB treatment landscape, how does a platform trial design accelerate the evaluation of agents like ganfeborole and BTZ-043, and what are the pharmacologic challenges of co-administering these with existing backbone drugs?

Key Response

Platform trials allow for the simultaneous, adaptive evaluation of multiple novel regimens against a shared control, significantly reducing time and sample size. Fellows must consider complex drug-drug interactions, such as overlapping toxicities (e.g., additive QTc prolongation with bedaquiline) or CYP450 induction/inhibition, which complicate the assembly and dosing of new multidrug regimens.

Attending
Attending

If subsequent Phase 3 trials confirm the efficacy and safety of ganfeborole- or BTZ-043-containing regimens, how might transitioning to ultra-short, pan-TB regimens disrupt current global TB eradication strategies and stewardship models?

Key Response

Ultra-short regimens (e.g., 2-3 months) would drastically reduce the operational burden of Directly Observed Therapy (DOT), improve adherence, and lower default rates. However, introducing 'pan-TB' regimens effective regardless of baseline resistance requires exceptional stewardship to prevent acquired resistance to these novel agents, necessitating robust global infrastructure for rapid molecular susceptibility testing.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

What are the methodological limitations of using time-to-positivity (TTP) in liquid culture or colony-forming unit (CFU) counting on solid media as primary endpoints for early bactericidal activity, and how could advanced molecular biomarkers improve predictive validity for long-term relapse?

Key Response

CFU counting is labor-intensive and prone to contamination, while TTP may fail to differentiate between dormant, non-culturable bacilli and dead bacilli. Evaluating RNA-based viability markers or lipidomic profiling could offer more sensitive, predictive surrogates for true sterilizing activity and long-term relapse risk compared to traditional culture methods, which often fall short in predicting Phase 3 success.

Journal Editor
Journal Editor

When evaluating a Phase 2 platform trial for TB, how should peer reviewers scrutinize the handling of missing longitudinal sputum data and the potential confounding effect of pharmacokinetic variability among diverse patient populations on the reported EBA slopes?

Key Response

Missing sputum samples or culture contamination can severely bias longitudinal EBA slopes. Furthermore, inter-individual PK variability (driven by pharmacogenomics, BMI, or gut absorption issues in severe TB) can lead to subtherapeutic exposures. A rigorous review must ensure the authors adequately performed PK/PD modeling and handled missing data using robust mixed-effects modeling rather than simple, potentially biased imputation methods.

Guideline Committee
Guideline Committee

Given current WHO guidelines prioritizing the 4-month BPaMZ or 6-month BPaL(M) regimens, what specific Phase 3 endpoints and evidence grades are required for a ganfeborole- or BTZ-043-based regimen to achieve a strong recommendation for replacing existing standard-of-care regimens?

Key Response

Current WHO guidelines require definitive Phase 3 non-inferiority or superiority data demonstrating high cure rates and low relapse at 12-18 months post-treatment. EBA data from Phase 2 only informs dose and regimen selection. To update guidelines, the committee requires large-scale randomized controlled trials proving these novel regimens can safely shorten therapy to 2-3 months or show superiority in multidrug-resistant populations without unacceptable toxicity, establishing a high certainty of evidence.

Clinical Landscape

Noteworthy Related Trials

2014

REMoxTB Trial

n = 1,931 · NEJM

Tested

Moxifloxacin substituted for ethambutol or isoniazid in a 4-month regimen

Population

Patients with drug-susceptible pulmonary tuberculosis

Comparator

Standard 6-month tuberculosis treatment regimen

Endpoint

Favorable outcome at 18 months

Key result: The experimental 4-month moxifloxacin regimens did not meet noninferiority criteria compared to the standard 6-month therapy.
2021

TBTC Study 31 / ACTG A5349

n = 2,516 · NEJM

Tested

4-month rifapentine-moxifloxacin regimen

Population

Patients with newly diagnosed pulmonary tuberculosis

Comparator

Standard 6-month regimen

Endpoint

Tuberculosis disease-free survival at 12 months

Key result: A 4-month regimen containing rifapentine and moxifloxacin was noninferior to the standard 6-month regimen in terms of disease-free survival.
2022

ZeNix Trial

n = 181 · NEJM

Tested

Bedaquiline, pretomanid, and varying doses of linezolid (BPaL)

Population

Patients with highly drug-resistant tuberculosis

Comparator

Different linezolid dosing strategies within the BPaL regimen

Endpoint

Treatment success and incidence of adverse events at 6 months

Key result: The BPaL regimen was highly effective across all linezolid dosing groups, and a lower dose or shorter duration of linezolid reduced toxic effects while maintaining efficacy.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis
↑